A team of scientists in the US have found that people who had heart conditions in middle-age were more likely to have memory and thinking problems in later life.
Research published today (Wednesday 25 January) in The BMJ found that people in their 60s who lead a healthier lifestyle experience slower cognitive decline.
Today (Wednesday 30 November) at the Clinical Trials on Alzheimer’s Disease Conference in San Francisco, the pharmaceutical company, Eisai, reports full data from its successful phase 3 clinical trial of the Alzheimer’s drug, lecanemab.
Researchers based in Chicago looked at the effects of antioxidants called flavonols on brain health in later life.
The pharmaceutical company Roche has announced that two phase III trials of the potential Alzheimer’s drug gantenerumab did not achieve the goal of slowing clinical decline in participants with early Alzheimer’s disease.
The ALBORADA Drug Discovery Institute (ADDI) announced that it will collaborate with pharmaceutical company YD Global Life Science (YDGLS) to develop inhibitors of the unfolded protein response for the treatment of the diseases that cause dementia.
Experienced Global Pharma Industry Leader, Prof Fiona Randall, joins the Alzheimer’s Research UK UCL Drug Discovery Institute as Chief Scientific Officer
Prof Fiona Randall has been appointed as Chief Scientific Officer (CSO) for Alzheimer’s Research UK’s University College London Drug Discovery Institute (UCL DDI)
Researchers in Canada have carried out a review of existing evidence of a link between dementia and air pollution.
Research published today (Wednesday 12 October) suggests that following a Mediterranean diet does not reduce risk of dementia, including Alzheimer’s disease and vascular dementia.
A new research study conducted in the US suggests that people who have higher levels omega-3 fatty acids in their blood during midlife have better thinking skills than people who have lower levels of the fatty acid.